Swiss National Bank Boosts Stock Holdings in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)

Swiss National Bank raised its holdings in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 14.0% during the second quarter, according to its most recent filing with the SEC. The firm owned 111,800 shares of the biotechnology company’s stock after purchasing an additional 13,700 shares during the period. Swiss National Bank owned 0.12% of Aurinia Pharmaceuticals worth $738,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Bank of America Corp DE grew its position in shares of Aurinia Pharmaceuticals by 8,600.6% in the 4th quarter. Bank of America Corp DE now owns 30,713 shares of the biotechnology company’s stock worth $210,000 after buying an additional 30,360 shares during the last quarter. Deutsche Bank AG grew its position in shares of Aurinia Pharmaceuticals by 413.2% in the 4th quarter. Deutsche Bank AG now owns 66,200 shares of the biotechnology company’s stock worth $451,000 after buying an additional 53,300 shares during the last quarter. Victory Capital Management Inc. purchased a new position in shares of Aurinia Pharmaceuticals in the 1st quarter worth approximately $45,000. Toronto Dominion Bank grew its position in shares of Aurinia Pharmaceuticals by 64.7% in the 1st quarter. Toronto Dominion Bank now owns 9,780 shares of the biotechnology company’s stock worth $63,000 after buying an additional 3,842 shares during the last quarter. Finally, Spark Investment Management LLC purchased a new position in shares of Aurinia Pharmaceuticals in the 1st quarter worth approximately $71,000. 31.96% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages have recently issued reports on AUPH. Oppenheimer began coverage on shares of Aurinia Pharmaceuticals in a research report on Tuesday. They issued an “outperform” rating and a $14.00 price objective on the stock. Zacks Investment Research downgraded shares of Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 16th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Thursday, August 8th. BidaskClub downgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, September 5th. Finally, Citigroup began coverage on shares of Aurinia Pharmaceuticals in a research report on Monday. They issued an “outperform” rating and a $14.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $15.18.



AUPH stock traded up $0.03 during trading on Friday, reaching $6.48. The company had a trading volume of 65,944 shares, compared to its average volume of 418,830. The firm has a 50-day simple moving average of $5.92 and a 200-day simple moving average of $6.29. The company has a market cap of $595.98 million, a price-to-earnings ratio of -8.53 and a beta of 1.12. Aurinia Pharmaceuticals Inc has a twelve month low of $5.06 and a twelve month high of $7.85.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.05 million. Aurinia Pharmaceuticals had a negative return on equity of 50.08% and a negative net margin of 13,231.97%. As a group, analysts expect that Aurinia Pharmaceuticals Inc will post -0.68 earnings per share for the current year.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

See Also: What is the Moving Average Convergence Divergence (MACD) oscillator?

Institutional Ownership by Quarter for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.